受全球新冠疫情影響，原定於5月29日~6月2日在芝加哥舉行的美國臨床腫瘤學會(ASCO)年會今年將首次以線上形式舉辦，這是目前最大規模的線上盛會。今天，會議的摘要題目公布，中國共有11項研究入選口頭報告，17項入選Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.

Session: Breast Cancer—Metastatic

Author(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou

Abstract: 1003

吡咯替尼或拉帕替尼加卡培他濱用於HER2+轉移性乳腺癌(PHOEBE)：一項III期隨機試驗。

專場：轉移性乳腺癌

作者：中國醫學科學院腫瘤醫院徐兵河教授、馬飛教授，複旦大學附屬腫瘤醫院胡夕春教授等

摘要號：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手術三陰性乳腺癌標準治療後卡培他濱維持節拍化療的III期試驗(SYSUCC-001)。

專場：乳腺癌—局部/區域/輔助治療

作者：中山大學腫瘤防治中心王樹森教授等

摘要號：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.

Session: New Tools to Combat Old Foes

Author(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun Chen

Abstract: 2507

利用轉移性腦腫瘤的表型特征來預測腦脊液中循環腫瘤DNA檢測的概率: 新工具對抗老對手

專場：新工具解決老問題

作者：李美芹 李德蘭等

摘要號: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多納非尼對比索拉非尼作為晚期肝細胞癌的一線治療：一項開放標簽、隨機、多中心II/III期試驗。

專場：胃腸道癌—胃食管、胰腺和肝膽

作者：四川大學華西醫院畢鋒教授、中國人民解放軍八一醫院秦叔逵教授等

摘要號：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中國晚期肝癌患者阿帕替尼二線治療：一項隨機、安慰劑對照、雙盲III期研究

專場：胃腸道癌—胃食管、胰腺和肝膽

作者：中國人民解放軍八一醫院秦叔逵教授、四川大學華西醫院李秋教授等

摘要號：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

晚期複發性卵巢癌二次腫瘤細胞減滅術的一項隨機III期試驗：SOC1 / SGOG-OV2。

專題：婦科癌症

作者：複旦大學附屬中山醫院臧榮餘教授等

摘要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宮頸癌根治性子宮切除術後輔助治療中的序貫放化療對比單獨放療或同步放化療(STARS研究)：一項隨機、對照、開放標簽的III期試驗。

會議：婦科癌症

作者：中山大學腫瘤防治中心黃鶴教授、劉繼紅教授等

摘要號：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：輔助吉非替尼對比化療用於可切除的EGFR突變的N1-N2期NSCLC-隨機III期臨床試驗的最終總體生存分析。

專題：肺癌—非小細胞局部-區域/小細胞/其他胸部腫瘤

作者：廣東省人民醫院吳一龍教授等

摘要號：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突變寡轉移非小細胞肺癌患者一線酪氨酸激酶抑製劑聯合或不聯合積極前線局部放療：III期開放標簽臨床隨機試驗(SINDAS)的中期結果(NCT02893332)。

專題：肺癌-非小細胞轉移

作者：四川省人民醫院曾銘教授等

摘要：9508

Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一種針對程序性死亡-1(PD-1)的人源化IgG4單克隆抗體聯合阿昔替尼用於轉移性黏膜黑色素瘤患者的Ib期研究的總生存期和生物標誌物分析。

專題：黑色素瘤/皮膚癌

作者：北京大學腫瘤醫院郭軍、盛錫楠教授等

摘要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).

Session: Developmental Therapeutics—Immunotherapy

Author(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi Zhang

Abstract: 3013

Poster: 77

GC027的安全性和療效結果：通用CAR-T細胞首次人體試驗治療成人複發/難治性T細胞急性淋巴細胞白血病(r/r T-ALL)的安全性和療效。

會議：開發中的治療技術-免疫治療。

作者：王欣欣等

摘要：3013

海報：77

Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi Wang

Abstract: 4511

Poster: 119

信迪利單抗在晚期食管鱗狀細胞癌患者中的應用：一項隨機的開放標簽II期試驗(ORIENT-2)。

會議：胃腸道癌-胃食管癌、胰腺癌和肝膽道癌

作者：徐建明教授等

摘要：4511

海報：119

Eradication of medulloblastoma by NKG2D-specific CAR T-cells.

Session: Central Nervous System Tumors

Author(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong Zhao

Abstract: 2522

Poster: 13

NKG2D特異性CAR-T細胞對髓母細胞瘤的根除性治療

會議：中樞神經係統腫瘤

作者：代紅久、孫斌、楊東、徐暉、朱晶晶、魏佳、趙旭東

摘要：2522

海報。13

Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.

Session: Developmental Therapeutics—Immunotherapy

Author(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, David Liu

Abstract: 3021

Poster: 85

Envafolimab(KN035)在晚期腫瘤錯配修複缺陷患者中的應用

會議：開發中的治療學-免疫治療

作者：沈琳教授等

摘要：3021

海報。85

First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.

Session: Developmental Therapeutics—Immunotherapy

Author(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen Zhang

Abstract: 3026

Poster: 90

自體CD7-CART治療複發/難治性ACUTE淋巴細胞白血病/淋巴瘤的首例人體臨床試驗

會議: 開發性治療學-免疫治療

作者簡介：張明誌，楊林等

摘要：3026

海報: 90

A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.

Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Author(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin Shen

Abstract: 3523

Poster: 253

西米替康(LP)單藥和5-氟尿嘧啶/白藜蘆醇(5-FU/LV)或沙利度胺(T)聯合應用於晚期實體瘤患者的Ib期研究

會議：發展性治療學--分子靶向藥物和腫瘤生物學

作者：龔繼芳，沈琳教授等

摘要：3523

海報：253

A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong Tan

Abstract: 4522

Poster: 130

Rh-endostatin聯合紫杉醇和nedaplatin治療複發性或轉移性食管鱗狀細胞癌(ESCC)患者的II期研究。

會議：胃腸道癌-胃食管、胰腺和肝膽道癌的研究

作者：王誌強，李玉紅，王德申，王鳳華，任超，譚瓊 王誌強、李玉紅、王德深、王鳳華、任超、譚瓊

摘要：4522

海報：130

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing Huang

Abstract: 4524

Poster: 132

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.

會議：胃腸道癌-胃食管癌、胰腺癌和肝膽管癌的二線治療

作者：宋豔等

摘要：4524

海報：132

A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.

Session: Genitourinary Cancer—Prostate, Testicular, and Penile

Author(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao Zhang

Abstract: 5522

Poster: 103

一種尿液外體環狀RNA分類器用於初始活檢時檢測高等級前列腺癌的尿液外體環狀RNA分類器：一項多中心的回顧性研究

會議：泌尿生殖係統癌症---前列腺癌、睾丸癌和陰莖癌

作者簡介：Liaoyuan Li等

摘要：5522

海報。103

Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.

Session: Gynecologic Cancer

Author(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin Li

Abstract: 6031

Poster: 202

局部晚期宮頸癌並發化療後的輔助化療

會議: 婦科癌症

作者簡介： 李瑉瑉等

摘要：6031

海報：202

Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An analysis based on the ALTER01031 trial.

Session: Head and Neck Cancer

Author(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng

Abstract: 6526

Poster: 187

降鈣素與安羅替尼治療甲狀腺髓性癌的療效相關性：基於ALTER01031試驗的分析。

會話：頭頸部腫瘤

作者：天津市腫瘤醫院高明教授

摘要：6526

海報。187

Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup analysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).

Session: Head and Neck Cancer

Author(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng

Abstract: 6527

Poster: 188

ECOG PS、腫瘤大小和年齡對安洛替尼治療後患者結局的影響: ALTER01031的亞組分析

會議：頭頸部腫瘤

作者：天津市腫瘤醫院高明教授

摘要：6527

海報。188

Circulating tumor DNA (ctDNA) analysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi Wu

Abstract: 9023

Poster: 216

ctDNA分析預測I-IIIA期非小細胞肺癌(NSCLC)患者術後複發: GASTO1035和GASTO1018的結果

會議：肺癌-非小細胞局部-區域性/小細胞/小細胞/其他胸科癌症

作者：Si-Yu Wang等

摘要：9023

海報：216

Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min Fan

Abstract: 9528

Poster: 294

ERBB2ΔEx16作為非小細胞肺癌(NSCLC)中EGFR酪氨酸激酶抑製劑的新型耐藥機製

會議:肺癌-非小細胞轉移性肺癌

作者簡介：趙昕，金玲玲，滿宇，歐秋香，華寶，薛武，楊少，範敏 趙昕、金玲玲、滿宇、歐秋香、華寶、薛武、楊紹、範敏

摘要：9528

海報：294

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.

Session: Melanoma/Skin Cancers

Author(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei Zhou

Abstract: 10030

Poster: 379

PD-1/PD-L1試驗中晚期黑色素瘤總生存的替代終點

會議：黑色素瘤/皮膚癌

作者：聶潤聰，袁書強，李元芳，陳英波，周誌偉 聶潤聰、袁書強、李元芳、陳英波、周誌偉

摘要：10030

海報：379

A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.

Session: Sarcoma

Author(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang Yao

Abstract: 11525

Poster: 413

安羅替尼治療複發或轉移性原發性惡性骨腫瘤患者的II期研究

會議： 肉瘤

作者：唐麗娜，牛曉輝，王震，蔡啟清，塗崇奇，範正福，楊瑤 唐麗娜、牛曉輝、王振、蔡啟慶、塗崇奇、範正福、楊瑤

摘要：11525

海報。413

Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.

Session: Sarcoma

Author(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying Niu

Abstract: 11526

Poster: 414

初步評價安羅替尼在晚期肉瘤患者多線治療中的安全性和療效。

會議：肉瘤

作者：姚偉濤，王家強，張鵬，王欣，杜新輝，田誌浩，牛曉穎 姚偉濤、王家強、張鵬、王鑫、杜鑫輝、田誌超、牛曉英

摘要：11526

海報：414